Table 1 Characteristics of patients in this substudy according to the treatment
Characteristic | FEC (N= 546) | FEC-D (N= 553) | P-value |
|---|---|---|---|
Age | Â | Â | 0.794 |
   <50 years | 261 (47.8%) | 260 (47.0%) |  |
   ≥50 years | 285 (51.2%) | 293 (53.0%) |  |
Menopausal status | Â | Â | 0.770 |
   Premenopausal | 332 (61.8%) | 331 (61.0%) |  |
   Postmenopausal | 214 (38.2%) | 222 (39.0%) |  |
Surgery | Â | Â | Â |
   Breast conservation | 313 (57.3%) | 342 (61.8%) | 0.127 |
   Modified mastectomy | 233 (42.7%) | 211 (38.2%) |  |
Pathological tumor size (pT) | Â | Â | Â |
   <2 cm | 163 (32.2%) | 200 (39.9%) | 0.039 |
   2 ≤pT <-5 cm | 306 (60.5%) | 269 (53.7%) |  |
   ≥5 cm | 37 (7.3%) | 32 (6.4%) |  |
SBR Grade | Â | Â | Â |
   I | 52 (9.6%) | 67 (12.2%) | 0.288 |
   II | 231 (42.6%) | 238 (43.2%) |  |
   III | 237 (43.7%) | 217 (39.4%) |  |
   Not gradable | 22 (4.1%) | 29 (5.3%) |  |
Positive lymph nodes | 329 (60.3%) | 342 (61.8%) | 0.589 |
   1 to 3 | 217 (39.7%) | 211 (38.2%) |  |
   ≥4 |  |  |  |
Hormone receptors | Â | Â | Â |
   Positive (ER and/or PR) | 414 (78.0%) | 419 (78.0%) | 0.981 |
   Negative (ER and PR) | 117 (22.0%) | 118 (22.0%) |  |
Estrogen receptor | Â | Â | Â |
   Positive | 394 (74.2%) | 391 (72.8%) | 0.607 |
   Negative | 137 (25.8%) | 146 (27.2%) |  |
Progesterone receptor | Â | Â | Â |
   Positive | 276 (52.0%) | 305 (56.7%) | 0.122 |
   Negative | 255 (48.0%) | 233 (43.3%) |  |
HER2 | Â | Â | Â |
   Positive | 93 (17.1%) | 82 (15.0%) | 0.337 |
   Negative | 451 (82.9%) | 466 (85.0%) |  |
DFS, event | Â | Â | Â |
   Yes | 150 (27%) | 118 (21%) | 0.021 |
   No | 396 (73%) | 435 (79%) |  |